News Center

Exclusive Sales Agency Agreement In Relation To Anti-Hair Loss Foam Product

Release time：2026-01-22 14:59

Suzhou, 21 January, 2026-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that Koshine Hong Kong Limited (the “Koshine Hong Kong”), a wholly-owned subsidiary of the Company, entered into an exclusive sales agency agreement (the “Sales Agency Agreement”) with Beijing Dekai Pharmaceutical Technology Co., Ltd* (北京德開醫藥科技有限公司) (the “Dekai Pharmaceutical”) in relation to the sales agency and market promotion (the “Business Cooperation”) of the Company’s anti-hair loss foam product in the Chinese Mainland market.

 

Pursuant to the Sales Agency Agreement, the Koshine Hong Kong and Dekai Pharmaceutical reached consensus on the sales agency and market promotion of the Company’s anti-hair loss foam product in the Chinese Mainland market. Drawing on their respective advantages and resources, the parties will establish a close cooperative relationship to jointly promote business expansion and product extension, achieving complementary advantages and synergistic development.

 

Dekai Pharmaceutical, established in 2012, is dedicated to leading retail innovation for pharmaceutical products in the new retail era. With chronic disease solutions as its core and empowered by big data capabilities, the Dekai Pharmaceutical specializes in creating bestsellers, continuously provides marketing empowerment for the industry chain while offering users health management services that cover all out-of-hospital channels, all scenarios and the entire life cycle.

 

As China's largest online community for chronic disease users, the DeKai Pharmaceutical has been deeply engaged in the "Internet + Healthcare" field for several years, and served a cumulative total of more than 25 million male-dominated chronic disease users, with the sales revenue of single product exceeding RMB100 million. The DeKai Pharmaceutical holds the pharmaceutical product registration certificates of minoxidil and ranks among the top players in China’s minoxidil market measured by its retail sales value. Leveraging the strong capabilities in industry chain integration and the strategic multi-channel deployment, the DeKai Pharmaceutical has built a robust pharmaceutical supply chain, including collaborations with over 2,000 pharmaceutical companies, and a professional chronic disease management team of nearly 100 members, managing nearly 2 million users with chronic disease. Meanwhile, the DeKai Pharmaceutical achieves a monthly content views of over 20 million through combination of original content and multi-media promotion matrix.

 

Dr. Youzhi Tong, the founder, chairman and CEO of Kintor Pharma, said,"This signing of the Sales Agency Agreement with DeKai Pharmaceutical is based on the highly complementary of resources and strategic synergy to each other, aiming to fully leverage the premium resources and capabilities of both parties to jointly explore the market and realize win-win values. Through this collaboration, the Company's anti-hair loss foam product will gain access to DeKai Pharmaceutical’s nationwide multi-channel sales network, enabling rapid outreach to its accumulated base of over 25 million male-dominated users with chronic disease and monthly traffic of tens of millions from active users. This will not only significantly shorten the market introduction cycle of product but also effectively enhance user trust and treatment compliance by leveraging DeKai’s professional chronic disease management system and education capabilities of patients with hair loss, and thereby driving simultaneous growth in sales and brand influence, from which the Group is expected to derive benefits. As such, the anti-hair loss foam product is expected to achieve leapfrog sales growth, striving to realize the sales target of exceeding RMB100 million."

Previous:

None

Next:

Completion Of Enrollment Of Subjects In Long-Term Human Safety Trial Of KT-939

recommend News

Kintor